| Breast cancer in young women: poor survival despite intensive treatment H Fredholm, S Eaker, J Frisell, L Holmberg, I Fredriksson, H Lindman PloS one 4 (11), e7695, 2009 | 624 | 2009 |
| Potent corticosteroid cream (mometasone furoate) significantly reduces acute radiation dermatitis: results from a double-blind, randomized study Å Boström, H Lindman, C Swartling, B Berne, J Bergh Radiotherapy and Oncology 59 (3), 257-265, 2001 | 322 | 2001 |
| Tailored fluorouracil, epirubicin, and cyclophosphamide compared with marrow-supported high-dose chemotherapy as adjuvant treatment for high-risk breast cancer: a randomised trial J Bergh, T Wiklund, B Erikstein, E Lidbrink, H Lindman, P Malmström, ... The Lancet 356 (9239), 1384-1391, 2000 | 305 | 2000 |
| First-in-human molecular imaging of HER2 expression in breast cancer metastases using the 111In-ABY-025 affibody molecule J Sörensen, D Sandberg, M Sandström, A Wennborg, J Feldwisch, ... Journal of nuclear medicine 55 (5), 730-735, 2014 | 270 | 2014 |
| Measuring HER2-receptor expression in metastatic breast cancer using [68Ga] ABY-025 Affibody PET/CT J Sörensen, I Velikyan, D Sandberg, A Wennborg, J Feldwisch, ... Theranostics 6 (2), 262, 2016 | 260 | 2016 |
| Effect of adjuvant trastuzumab for a duration of 9 weeks vs 1 year with concomitant chemotherapy for early human epidermal growth factor receptor 2–positive breast cancer: the … H Joensuu, J Fraser, H Wildiers, R Huovinen, P Auvinen, M Utriainen, ... JAMA oncology 4 (9), 1199-1206, 2018 | 174 | 2018 |
| Adjuvant capecitabine, docetaxel, cyclophosphamide, and epirubicin for early breast cancer: final analysis of the randomized FinXX trial H Joensuu, PL Kellokumpu-Lehtinen, R Huovinen, A Jukkola-Vuorinen, ... Journal of clinical oncology 30 (1), 11-18, 2012 | 153 | 2012 |
| Adherence and discontinuation of adjuvant hormonal therapy in breast cancer patients: a population-based study A Wigertz, J Ahlgren, M Holmqvist, T Fornander, J Adolfsson, H Lindman, ... Breast cancer research and treatment 133, 367-373, 2012 | 151 | 2012 |
| Long-term outcome in young women with breast cancer: a population-based study H Fredholm, K Magnusson, LS Lindström, H Garmo, SE Fält, H Lindman, ... Breast cancer research and treatment 160, 131-143, 2016 | 129 | 2016 |
| Biodistribution and radiation dosimetry of the anti-HER2 affibody molecule 68Ga-ABY-025 in breast cancer patients M Sandström, K Lindskog, I Velikyan, A Wennborg, J Feldwisch, ... Journal of Nuclear Medicine 57 (6), 867-871, 2016 | 125 | 2016 |
| Urogenital disorders in women with adjuvant endocrine therapy after early breast cancer J Baumgart, K Nilsson, A Stavreus-Evers, K Kask, K Villman, H Lindman, ... American journal of obstetrics and gynecology 204 (1), 26. e1-26. e7, 2011 | 95 | 2011 |
| Adjuvant capecitabine in combination with docetaxel, epirubicin, and cyclophosphamide for early breast cancer: the randomized clinical FinXX trial H Joensuu, PL Kellokumpu-Lehtinen, R Huovinen, A Jukkola-Vuorinen, ... JAMA oncology 3 (6), 793-800, 2017 | 94 | 2017 |
| Adjuvant capecitabine in combination with docetaxel and cyclophosphamide plus epirubicin for breast cancer: an open-label, randomised controlled trial H Joensuu, PL Kellokumpu-Lehtinen, R Huovinen, A Jukkola-Vuorinen, ... The lancet oncology 10 (12), 1145-1151, 2009 | 92 | 2009 |
| Bisphosphonate treatment in primary breast cancer: results from a randomised comparison of oral pamidronate versus no pamidronate in patients with primary breast cancer B Kristensen, B Ejlertsen, HT Mouridsen, MB Jensen, J Andersen, ... Acta oncologica 47 (4), 740-746, 2008 | 92 | 2008 |
| Population analysis of the pharmacokinetics and the haematological toxicity of the fluorouracil-epirubicin-cyclophosphamide regimen in breast cancer patients M Sandström, H Lindman, P Nygren, M Johansson, J Bergh, MO Karlsson Cancer chemotherapy and pharmacology 58, 143-156, 2006 | 91 | 2006 |
| Molecular subtypes in ductal carcinoma in situ of the breast and their relation to prognosis: a population-based cohort study W Zhou, K Jirström, RM Amini, ML Fjällskog, T Sollie, H Lindman, T Sørlie, ... BMC cancer 13, 1-9, 2013 | 82 | 2013 |
| Model describing the relationship between pharmacokinetics and hematologic toxicity of the epirubicin-docetaxel regimen in breast cancer patients M Sandstrom, H Lindman, P Nygren, E Lidbrink, J Bergh, MO Karlsson Journal of clinical oncology 23 (3), 413-421, 2005 | 82 | 2005 |
| U-CAN: a prospective longitudinal collection of biomaterials and clinical information from adult cancer patients in Sweden B Glimelius, B Melin, G Enblad, I Alafuzoff, A Beskow, H Ahlström, ... Acta oncologica 57 (2), 187-194, 2018 | 77 | 2018 |
| Node-positive left-sided breast cancer patients after breast-conserving surgery: potential outcomes of radiotherapy modalities and techniques J Johansson, U Isacsson, H Lindman, A Montelius, B Glimelius Radiotherapy and oncology 65 (2), 89-98, 2002 | 75 | 2002 |
| Characterization of endogenous G-CSF and the inverse correlation to chemotherapy-induced neutropenia in patients with breast cancer using population modeling AL Quartino, MO Karlsson, H Lindman, LE Friberg Pharmaceutical research 31, 3390-3403, 2014 | 62 | 2014 |
